Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19591007 | 0.75 | CYP11B1 (0.49) | CYP11B1CYP11B2LOXL2 | |
| SCHEMBL27429817 | 0.73 | CYP11B1 (0.40) | FLT1KDRCYP11B1CYP11B2 | |
| SCHEMBL19841610 | 0.70 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL21467096 | 0.69 | KCNH3 (0.35) | FLT1KDRLOXL2 | |
| SCHEMBL25036501 | 0.69 | HTR2C (0.32) | — | |
| SCHEMBL21498910 | 0.68 | TSHR (0.35) | FLT1KDRCYP11B1CYP11B2 | |
| SCHEMBL21710072 | 0.67 | GRM4 (0.33) | — | |
| SCHEMBL18459205 | 0.67 | L3MBTL1 (0.53) | — | |
| SCHEMBL533421 | 0.66 | CALM1 (0.44) | FLT1KDRCYP11B1CYP11B2 | |
| SCHEMBL19414362 | 0.66 | FYN (0.49) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126391-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO[4.3.1] DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-04-27 | — | — | US | disclosed |
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126391-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO[4.3.1] DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP8, FKBP2, FKBP1A | FLT1 4399/4885KDR 4358/4885CYP11B1 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.